Compare EW & NDAQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EW | NDAQ |
|---|---|---|
| Founded | 1958 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.6B | 54.9B |
| IPO Year | 1999 | 2001 |
| Metric | EW | NDAQ |
|---|---|---|
| Price | $106.66 | $108.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 30 | 18 |
| Target Price | $113.39 | ★ $115.38 |
| AVG Volume (30 Days) | ★ 4.4M | 3.5M |
| Earning Date | 11-04-2026 | 10-22-2026 |
| Dividend Yield | N/A | ★ 1.14% |
| EPS Growth | N/A | ★ 60.10 |
| EPS | 1.61 | ★ 2.76 |
| Revenue | ★ $6,067,600,000.00 | $4,277,000,000.00 |
| Revenue This Year | $12.23 | $12.85 |
| Revenue Next Year | $9.84 | $9.06 |
| P/E Ratio | $66.63 | ★ $39.19 |
| Revenue Growth | ★ 11.55 | 7.87 |
| 52 Week Low | $74.66 | $76.55 |
| 52 Week High | $107.69 | $111.45 |
| Indicator | EW | NDAQ |
|---|---|---|
| Relative Strength Index (RSI) | 77.78 | 64.42 |
| Support Level | $82.21 | $104.91 |
| Resistance Level | N/A | $111.45 |
| Average True Range (ATR) | 3.38 | 2.17 |
| MACD | 1.06 | -0.15 |
| Stochastic Oscillator | 93.83 | 58.45 |
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its trading business (about 22.5% of sales), the company sells market and financial data to investors, offers Nasdaq-branded indexes, and lists companies through its capital access segment (42.5%). Nasdaq's newest segment, financial technology, was primarily constructed through the acquisitions of Verafin and Adenza and has expanded the company into capital management, financial crime, and regulatory compliance software (35%) as it seeks to become a diversified technology company.